Copyright © Inderes 2011 - present. All rights reserved.

Genovis

25,65

 

SEK

 

+1,38 %

GENO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

1.661 investorer følger denne virksomhed
Sammenligne
+1,38%
-4,11%
+13%
-20,09%
-50,67%
-47,92%
-62,72%
-5%
-6,31%

Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.

Læs mere
Markedsværdi
1,68 mia. SEK
Aktieomsætning
460,97 t SEK
Omsætning
158,23 mio.
EBIT %
34,27 %
P/E
27,29
Udbytteafkast, %
-
Finanskalender
14.2
2025

Årsrapport '24

21.5
2025

Delårsrapport Q1'25

12.8
2025

Delårsrapport Q2'25

ViserAlle indholdstyper

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account